Physician profile
Carol Yu
NPI 1639697451
$4,049.58
in general payments reported to CMS, 2019-2025
21 companies · $624 in 2025
The $624 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $125 · 2021: $611 · 2022: $953 · 2023: $383 · 2024: $628 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $640.32 | 2022-2025 | Infuse, Alden Scleral Zenlens, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $582.35 | 2019-2021 | |
| Coopervision INC. | $469.83 | 2019-2025 | Onefit Contact Lens, Ortho-K Contact Lens |
| Amgen INC. | $467.43 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $264.95 | 2022 | |
| Allergan, INC. | $248.82 | 2021-2022 | |
| Visioneering Technologies, INC. | $206.88 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $144.33 | 2019-2023 | |
| Synergeyes, INC. | $137.10 | 2021-2022 | |
| Astellas Pharma US INC | $136.02 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $122.49 | 2019 | |
| Shire North American Group INC | $120.43 | 2019 | |
| Glaukos Corporation | $107.53 | 2021-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $98.29 | 2022 | |
| Alcon Vision LLC | $79.30 | 2022-2025 | Total30, Dailies Total1 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $72.42 | 2025 | Xdemvy |
| Harrow Eye, LLC | $68.99 | 2025 | Vevye |
| Dompe US, INC. | $28.29 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $21.69 | 2024 | |
| Abbvie INC. | $17.45 | 2023 | Vuity, Alphagan P, Lumigan |
| Mallinckrodt Hospital Products INC. | $14.67 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.